| Median age (IQR), years |
73 (67-76) |
| Biopsy Gleason Score, n (%) |
|
| ≤7 |
11 (17.4) |
| 8 |
11 (17.4) |
| ≥9 |
41 (65.2) |
| NA |
3 |
| Prior local therapy, n (%) |
|
| Presence |
19 (28.8) |
| Absence |
47 (71.2) |
| Measurable disease, n (%) |
46 (69.7%) |
| Pain, n (%) |
30 (45.4%) |
| Progression on docetaxel <6 months, n (%) |
54 (81.8) |
| Number of docetaxel cycles, median (IQR) |
7 (5-10) |
| Prior treatment for CRPC, n (%) |
|
| Abiraterone/Enzalutamide |
56 (84.5) |
| Radium-223 |
4 (6.06) |
| Performance status |
|
| 0 |
43 (65.1%) |
| 1 |
15 (22.7%) |
| 2 |
8 (12.2%) |
| Median time on hormone treatment (IQR), years |
3.54 (2.23-6.74) |
| Median hemoglobin (IQR), g/dL |
12.1 (10.9-12.9) |
| Median alkaline phosphatase (IQR), IU/L |
288 (204-496) |
| Median PSA (IQR), ng/mL |
59.1 (18.1-176.4) |
| Metastatic sites, n (%) |
| Bone |
58 (87.8) |
| Lymph node |
39 (59.1) |
| Visceral |
18 (27.2%) |
| Number of cabazitaxel cycles, median (IQR) |
5 (3-8) |
